Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Till portföljen: Wall Street-banken pekar ut sex utdelningshöjare – historiskt en vinnarsignal

Analyser av Corline Biomedical

Kurs från TradingView
Visa mer ▼
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Corline Biomedical (Q2 Review): Early stages of the Globe ramp-up - Redeye

Redeye provides an update following Corline’s Q2 2026 report.

Redeye • 27 aug 07:04

Corline Biomedical (Q2 Initial take): Lower sales than expected, but long-term case intact - Redeye

Redeye provides an initial take following the release of Corline’s Q2 2026 report.

Redeye • 26 aug 09:34

Corline Biomedical: Regulatory approval in Canada - Redeye

Redeye is positive about Kardium’s regulatory approval in Canada for the Globe system.

Redeye • 10 aug 09:59

Corline Biomedical: Five-year follow-up data on Renaparin - Redeye

Redeye is positive about Renaparin’s five-year follow-up data.

Redeye • 03 jul 07:07

Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration - Redeye

Redeye provides an update following Corline’s Q1 2026 report.

Redeye • 11 maj 07:11

Corline Biomedical (Q1 Initial take): Signs of sales ramp-up - Redeye

Redeye provides an initial take following the release of Corline’s Q1 2026 report.

Redeye • 08 maj 09:36

Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence - Redeye

Redeye provides an update following Corline’s Q4 2025 report.

Redeye • 18 feb 07:23

Corline Biomedical Q4 (Initial take): Waiting for the sales ramp-up - Redeye

Redeye provides an initial take following the release of Corline’s Q4 2025 report.

Redeye • 17 feb 09:29

Corline Biomedical: Directed share issue and loan agreement with Kardium - Redeye

Redeye is positive about Corline’s directed share issue and loan agreement with Kardium.

Redeye • 09 jan 11:45

Corline Biomedical Q3 (Review): Sales growth incoming - Redeye

Redeye provides an update following Corline’s Q3 2025 report.

Redeye • 19 nov 2025 07:09

Corline Biomedical Q3 (Initial take): No sales ramp-up this quarter, but only a matter of time - Redeye

Redeye provides an initial take following the release of Corline’s Q3 2025 report.

Redeye • 18 nov 2025 09:32

Corline Biomedical: Directed share issue at solid terms - Redeye

Redeye comments on Corline’s directed share issue, which raises SEK23m and strengthens the shareholder base.

Redeye • 09 okt 2025 07:26

Corline Biomedical: Going global - Redeye

Redeye is positive about Corline’s and Kardium’s development with a new ten-year agreement, and that Kardium has now initiated the commercia...

Redeye • 03 okt 2025 07:21

Corline Biomedical: Ten-year licensing and supply agreement with Kardium - Redeye

Redeye is positive about Corline’s new licensing and supply agreement with Kardium, which underlines the importance of Corline’s CHS surface...

Redeye • 01 okt 2025 08:05

Corline Biomedical: Kardium receives FDA approval - Redeye

Redeye is positive about Kardium’s FDA approval for the Globe system, which allows the commercial phase to begin.

Redeye • 02 sep 2025 07:20

Corline Biomedical Q2: Kardium’s Globe system nearing launch - Redeye

Redeye provides an update following Corline’s Q2 2025 report.

Redeye • 27 aug 2025 07:29

Corline Biomedical Q2: Initial take – Sales a bit soft, but no major surprises overall - Redeye

Redeye provides an initial take following the release of Corline’s Q2 2025 report.

Redeye • 26 aug 2025 09:37

Corline Biomedical: Kardium raises USD250m to support the Globe launch - Redeye

Redeye comments on Kardium’s capital injection of USD250m.

Redeye • 03 jul 2025 07:27

Corline Biomedical Q1: Exciting quarters ahead - Redeye

Redeye provides an update following Corline’s Q1 2025 report.

Redeye • 09 maj 2025 10:52

Corline Biomedical Q1: Initial take – Fairly in line with our expectations - Redeye

Redeye provides an initial take following the release of Corline’s Q1 2025 report.

Redeye • 08 maj 2025 11:47

Corline Biomedical: Solid 1-year study results from Kardium - Redeye

Redeye comments on Kardium's 1-year study results for its CHS-coated Globe system.

Redeye • 28 apr 2025 11:36

Corline Biomedical Q4: Focus on Kardium’s market launch - Redeye

Redeye provides an update following Corline’s Q4 2024 report.

Redeye • 18 feb 2025 07:18

Corline Biomedical: Short-term triggers to unlock value - Redeye

Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in coating solutions for the medical technol...

Redeye • 04 feb 2025 07:26

Corline Biomedical: Svag försäljning, god kostnadskontroll - Penser Access by Carnegie

Låg försäljning, men god progression hos kunder Corline levererade en svag försäljning men god kostnadskontroll under det första kvartalet.

Penser • 03 maj 2024 09:49

Corline Biomedical: Inga överraskningar – på ett bra sätt - Penser Access by Carnegie

Q4 – fortsatt stabilitet i försäljningen Corlines Q4-rapport var i linje med våra förväntningar.

Penser • 15 feb 2024 10:10

Corline Biomedical: Lönsamhet i fokus - Penser

Rapportkommentar Q3 Corlines Q3-rapport levde inte upp till marknadens förväntningar.

Penser • 14 nov 2023 11:18

Corline Biomedical: Spännande höst väntar - Penser

Q2 - något under förväntan Corline levererade under torsdagen en rapport något under våra förväntningar.

Penser • 28 aug 2023 11:48

Corline Biomedical: Imponerande avtal - Penser

Framsteg med Imperative Care Corline meddelade under torsdagen att de ingått ett avtal med Imperative Care avseende licensrättigheter till b...

Penser • 05 maj 2023 11:05

Corline Biomedical: Snart dags för Renaparin - Penser

Fortsatt starkt på intäktssidan Corline levererade under torsdagen en stark rapport som var i linje med våra förväntningar.

Penser • 03 maj 2023 11:47

Corline Biomedical: Fortsatt uppmuntrande utveckling - Penser

Bra momentum i försäljningen Corline rapporterade under fredagen ett omsättningsrekord för tredje kvartalet i rad.

Penser • 27 feb 2023 11:08

Corline Biomedical: Solid utveckling - Penser

Rapportkommentar Q2 Corline presenterade igår en positiv Q2-rapport som visade på en stabil försäljningstillväxt och god kostnadskontroll.

Penser • 26 aug 2022 11:16

Corline Biomedical: I en positiv trend - Penser

Rapportkommentar Corline levererade en rapport för Q1 2022 som var i linje med våra förväntningar.

Penser • 17 maj 2022 11:39

Corline Biomedical: Stark avslutning på året - Penser

Ökade volymer inom medicinteknik Corline presenterade nyligen sin Q4-rapport som överträffade våra förväntningar.

Penser • 24 feb 2022 12:44

Corline Biomedical: I rätt riktning - Penser

En rapport i linje med våra förväntningar Corline presenterade under gårdagen sin rapport för det tredje kvartalet.

Penser • 26 nov 2021 11:42

Corline Biomedical: Förlänger avtal med kund - Penser

Förlängt avtal Corline meddelade under morgonen att bolaget har förlängt avtalet med Imperative Care avseende produktleveranser av CHS-belag...

Penser • 15 okt 2021 12:18

Corline Q2 confirms increasing future potential - Redeye

Redeye’s points to more robust potential partner support for CHS coated medical devices.

Redeye • 25 aug 2021 14:08